YEAR IN REVIEW 2022

**Purpose:** This report provides cumulative and updated statistics about the emergence and landscape of novel psychoactive substances (NPS) in the United States based on data developed by NPS Discovery at the CFSRE — a premier open-access drug early warning system utilizing an evidence-based approach to disseminate information for real-time public health and safety actions.

Since 2018, NPS Discovery has reported 137 newly discovered NPS in the United States (Figure 1). **NPS opioids** remain the largest subclass (Figure 2). In 2022, NPS Discovery reported the discovery of 21 NPS for the first time.

Since 2018, NPS Discovery has identified 218 NPS in forensic samples (Figure 3). **NPS opioids**, **stimulants**, and **cannabinoids** represent the largest subclasses observed. In 2022, 76 total NPS were detected (Figure 4).

In 2022, NPS Discovery observed more than 2,200 total NPS detections within examined sample populations (Figure 5), a portion of more than 10,000 total NPS detections since our program launched in 2018 (Figure 6).